BACKGROUND: Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. METHODS: In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors. RESULTS: After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction<.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer. CONCLUSION: A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
BACKGROUND: Lower activated partial thromboplastin times are associated with higher levels of some coagulation factors and may represent a procoagulant tendency. METHODS: In the Atherosclerosis Risk in Communities study, we studied the 13-year risk of venous thromboembolism in relation to baseline activated partial thromboplastin time in 13,880 individuals. We also studied 258 venous thromboembolism cases and 589 matched controls with measurements of additional coagulation factors. RESULTS: After adjustment for demographics and procoagulant factors reflected in the activated partial thromboplastin time (fibrinogen, factors VIII, IX, and XI, and von Willebrand factor), participants in the lowest 2 quartiles of activated partial thromboplastin time compared with the fourth quartile had 2.4-fold (95% confidence interval [CI], 1.4-4.2) and 1.9-fold (95% CI, 1.1-3.2) higher risks of venous thromboembolism. The risk associated with activated partial thromboplastin times below the median was higher for idiopathic (odds ratio 5.5; 95% CI, 2.0-15.5) than secondary venous thromboembolism (odds ratio 1.74; 95% CI, 0.88-3.43). Subjects with both activated partial thromboplastin times below the median and factor V Leiden were 12.6-fold (95% CI, 5.7-28.0) more likely to develop venous thromboembolism compared with those with neither risk factor (P interaction<.01). A lower activated partial thromboplastin time also added to the thrombosis risk associated with obesity and elevated D-dimer. CONCLUSION: A single determination of the activated partial thromboplastin time below the median increased the risk of future venous thromboembolism. Findings were independent of coagulation factor levels, and a low activated partial thromboplastin time added to the risk associated with other risk factors.
Authors: I Bank; E J Libourel; S Middeldorp; K Hamulyák; E C M van Pampus; M M W Koopman; M H Prins; J van der Meer; H R Büller Journal: J Thromb Haemost Date: 2005-01 Impact factor: 5.824
Authors: Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Russell P Tracy; Nena Aleksic; Aaron R Folsom Journal: Am J Med Date: 2002-12-01 Impact factor: 4.965
Authors: A R Folsom; W Tang; N S Roetker; A V Kshirsagar; V K Derebail; P L Lutsey; R Naik; J S Pankow; M L Grove; S Basu; N S Key; M Cushman Journal: J Thromb Haemost Date: 2014-12-11 Impact factor: 5.824
Authors: Weihong Tang; Christine Schwienbacher; Lorna M Lopez; Yoav Ben-Shlomo; Tiphaine Oudot-Mellakh; Andrew D Johnson; Nilesh J Samani; Saonli Basu; Martin Gögele; Gail Davies; Gordon D O Lowe; David-Alexandre Tregouet; Adrian Tan; James S Pankow; Albert Tenesa; Daniel Levy; Claudia B Volpato; Ann Rumley; Alan J Gow; Cosetta Minelli; John W G Yarnell; David J Porteous; John M Starr; John Gallacher; Eric Boerwinkle; Peter M Visscher; Peter P Pramstaller; Mary Cushman; Valur Emilsson; Andrew S Plump; Nena Matijevic; Pierre-Emmanuel Morange; Ian J Deary; Andrew A Hicks; Aaron R Folsom Journal: Am J Hum Genet Date: 2012-06-14 Impact factor: 11.025
Authors: Aaron R Folsom; Pamela L Lutsey; Brad C Astor; Keattiyoat Wattanakit; Susan R Heckbert; Mary Cushman Journal: Nephrol Dial Transplant Date: 2010-03-29 Impact factor: 5.992
Authors: Aaron R Folsom; Pamela L Lutsey; Nicholas S Roetker; Wayne D Rosamond; Mariana Lazo; Susan R Heckbert; Saonli Basu; Mary Cushman; Elizabeth Selvin Journal: Ann Epidemiol Date: 2014-09-08 Impact factor: 3.797
Authors: Aaron R Folsom; Pamela L Lutsey; Nicholas S Roetker; Christie M Ballantyne; Ron C Hoogeveen; Wayne D Rosamond; Mary Cushman Journal: Thromb Res Date: 2013-06-06 Impact factor: 3.944
Authors: A R Folsom; N S Roetker; W D Rosamond; S R Heckbert; S Basu; M Cushman; P L Lutsey Journal: J Thromb Haemost Date: 2014-08-11 Impact factor: 5.824